Ligand Pharmaceuticals Stock - Insider option exercise and institutional selling
17.06.2026 - 16:49:06 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 16:47 CET. Details in the imprint.
Ligand Pharmaceuticals (US53220K1060) is drawing attention after fresh disclosures on insider option exercises and institutional selling. A recent filing highlights a sizable share sale by Ashford Capital Management and option exercises by company insiders, according to recent market reports.
All news and analysis on Ligand Pharmaceuticals stock
Key filings, earnings releases and market data on Ligand Pharmaceuticals are bundled in the ad-hoc-news topic overview and on the company’s own Investor Relations page.
What the latest filings show
Ashford Capital Management recently reported selling 30,652 Ligand Pharmaceuticals shares in a Form 13F-related disclosure, with the position change highlighted in an institutional holdings update. The MarketBeat report on Ashford’s sale states that Ligand shares opened around $255 on the day of the note.
In a separate insider transaction, an article summarizing recent activity reports that executive Jason Haas exercised stock options tied to 4,000 shares, with an estimated value of just over $800,000 at the time of the move. A Benzinga summary details the Haas option exercise and notes that the transaction was framed as part of a strategic sale.
How analysts currently value Ligand
Analyst coverage on Ligand Pharmaceuticals remains relatively concentrated among a small group of US brokerages, with recent consensus data indicating a mix of Buy and Hold ratings and a wide spread in 12-month price targets. MarketBeat’s consensus overview for LGND shows that the average target sits meaningfully above the 200-day moving average, underscoring expectations for long-term royalty growth.
The company is followed primarily by mid-sized research houses rather than the largest Wall Street firms, which can mean less frequent target updates but also a sharper focus on Ligand’s licensing and royalty pipeline. For retail investors, the dispersion of estimates underlines that views on valuation differ quite materially.
What the company sells
Ligand Pharmaceuticals centers its business on acquiring and managing drug royalty streams, licensing technologies such as its Captisol platform to larger pharmaceutical companies and in return earning milestone and ongoing royalty payments on partnered therapies.
Where the stock trades today
The shares of Ligand Pharmaceuticals (US53220K1060) trade on Nasdaq at $255.25 as of 06/17/2026, 16:30 CET.
Key facts on Ligand Pharmaceuticals stock
- Company: Ligand Pharmaceuticals Incorporated
- ISIN: US53220K1060
- WKN: 896663
- Ticker: LGND
- Venue: Nasdaq
- Price (as of 06/17/2026, 16:30 CET): 255.25 USD
- Market cap: 4,350,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not included in the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
